Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
AstraZeneca
Johnson and Johnson
McKinsey
Colorcon

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR PERIOSTAT


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Periostat

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00041977 ↗ Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea Completed CollaGenex Pharmaceuticals Phase 3 2002-06-01 The purpose of this study is to determine whether Periostat(R), Doxycycline Hyclate 20 mg Tablets, taken twice daily is effective in reducing the red and white heads and overall redness associated with rosacea.
NCT00246740 ↗ Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting Completed University of Alberta Phase 2 2005-10-01 The purpose of this study is to determine whether doxycycline (Periostat) at a sub-antimicrobial dose will decrease reperfusion injury after coronary artery bypass grafting (CABG) surgery with cardiopulmonary bypass (CPB).
NCT00358462 ↗ Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA) Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 2007-01-01 The purpose of this study is to find out which of 2 different antibiotics, doxycycline or azithromycin, works best against germs that may cause nongonococcal urethritis. Study participants will include approximately 1200 men, 16 years of age or older, attending a sexually transmitted diseases clinic in Seattle, Washington with clinical signs of urethral inflammation (>=5PMNs/HPF on a Gram-stained slide prepared from urethral exudates and/or a visible urethral discharge upon examination). Urine specimens will be collected and tested for Mycoplasma genitalium and Ureaplasmas. Each participant will receive a blinded packet of study medication. Participants will answer an enrollment questionnaire and will also receive a log to complete between visits to record information about treatment adherence, side effects, symptoms, and sexual activity. All subjects will be asked to return for evaluation 3 weeks after the initial clinic visit. Subjects who test positive for M. genitalium and/or Ureaplasmas at the initial clinic visit will also be asked to return for a third study visit, 6 weeks following the initial clinic visit. During follow-up visits, participants will answer a follow-up questionnaire and will be re-evaluated for signs of urethritis. Those who were initially positive for M. genitalium and/or Ureaplasmas will be re-tested for these organisms. Study participants with signs and/or symptoms of urethritis or who test positive for M. genitalium or Ureaplasmas at the follow-up study visit will receive another blinded treatment packet containing the alternate medication. Those who require additional treatment at the 6-week visit will be asked to return for a fourth follow-up study visit at 9-10 weeks. Study participants who did not test positive for M. genitalium or Ureaplasmas at the initial clinic visit, but who continue to demonstrate signs and/or symptoms of infection at their single follow-up study visit will treated according to clinic standard of care (after the study clinician unblinds their randomly-assigned treatment regimen).
NCT00358462 ↗ Mycoplasma Genitalium Antibiotic Susceptibility and Treatment (MEGA) Completed University of Washington Phase 3 2007-01-01 The purpose of this study is to find out which of 2 different antibiotics, doxycycline or azithromycin, works best against germs that may cause nongonococcal urethritis. Study participants will include approximately 1200 men, 16 years of age or older, attending a sexually transmitted diseases clinic in Seattle, Washington with clinical signs of urethral inflammation (>=5PMNs/HPF on a Gram-stained slide prepared from urethral exudates and/or a visible urethral discharge upon examination). Urine specimens will be collected and tested for Mycoplasma genitalium and Ureaplasmas. Each participant will receive a blinded packet of study medication. Participants will answer an enrollment questionnaire and will also receive a log to complete between visits to record information about treatment adherence, side effects, symptoms, and sexual activity. All subjects will be asked to return for evaluation 3 weeks after the initial clinic visit. Subjects who test positive for M. genitalium and/or Ureaplasmas at the initial clinic visit will also be asked to return for a third study visit, 6 weeks following the initial clinic visit. During follow-up visits, participants will answer a follow-up questionnaire and will be re-evaluated for signs of urethritis. Those who were initially positive for M. genitalium and/or Ureaplasmas will be re-tested for these organisms. Study participants with signs and/or symptoms of urethritis or who test positive for M. genitalium or Ureaplasmas at the follow-up study visit will receive another blinded treatment packet containing the alternate medication. Those who require additional treatment at the 6-week visit will be asked to return for a fourth follow-up study visit at 9-10 weeks. Study participants who did not test positive for M. genitalium or Ureaplasmas at the initial clinic visit, but who continue to demonstrate signs and/or symptoms of infection at their single follow-up study visit will treated according to clinic standard of care (after the study clinician unblinds their randomly-assigned treatment regimen).
NCT02388477 ↗ Trial of the Use of Doxycycline After Rotator Cuff Repair Withdrawn Milton S. Hershey Medical Center N/A 1969-12-31 The purpose of this study is to examine healing after rotator cuff repair in subjects either treated with Doxycycline or placebo post-operatively.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Periostat

Condition Name

Condition Name for Periostat
Intervention Trials
Malignant Neoplasms of Respiratory and Intrathoracic Organs 2
Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites 1
Rotator Cuff Injury 1
Malignant Neoplasms of Independent (Primary) Multiple Sites 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Periostat
Intervention Trials
Pleural Effusion, Malignant 2
Neoplasms 2
Pleural Effusion 2
Pleural Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Periostat

Trials by Country

Trials by Country for Periostat
Location Trials
United States 9
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Periostat
Location Trials
Texas 3
Pennsylvania 2
Washington 1
Virginia 1
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Periostat

Clinical Trial Phase

Clinical Trial Phase for Periostat
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 2 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Periostat
Clinical Trial Phase Trials
Completed 3
Recruiting 2
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Periostat

Sponsor Name

Sponsor Name for Periostat
Sponsor Trials
M.D. Anderson Cancer Center 3
CollaGenex Pharmaceuticals 1
University of Alberta 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Periostat
Sponsor Trials
Other 6
Industry 3
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Mallinckrodt
Johnson and Johnson
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.